Carregant...

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial evaluated the efficacy and safety of high-specific-activity (131)I-meta-iodobenzylguanidine (HSA (131)I-MIBG) in patients with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Nucl Med
Autors principals: Pryma, Daniel A., Chin, Bennett B., Noto, Richard B., Dillon, Joseph S., Perkins, Stephanie, Solnes, Lilja, Kostakoglu, Lale, Serafini, Aldo N., Pampaloni, Miguel H., Jensen, Jessica, Armor, Thomas, Lin, Tess, White, Theresa, Stambler, Nancy, Apfel, Stuart, DiPippo, Vincent A., Mahmood, Syed, Wong, Vivien, Jimenez, Camilo
Format: Artigo
Idioma:Inglês
Publicat: Society of Nuclear Medicine 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6495236/
https://ncbi.nlm.nih.gov/pubmed/30291194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.217463
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!